Your session is about to expire
← Back to Search
Diagnostic Test
PillSense (Active) for Upper Gastrointestinal Bleed
N/A
Waitlist Available
Research Sponsored by EnteraSense Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 through day 14
Awards & highlights
Study Summary
This is a prospective, non-randomized, open-label clinical investigation to evaluate feasibility, effectiveness and safety of the PillSense System, the transit of the PillSense Capsule through the GI tract, patient tolerability of the PillSense Capsule, and blood detection.
Eligible Conditions
- Upper Gastrointestinal Bleed
- Upper Gastrointestinal Bleeding
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1 through day 14
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 through day 14
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Sensitivity
Specificity
Secondary outcome measures
NPV
PPV
Transit
Trial Design
1Treatment groups
Experimental Treatment
Group I: PillSense (Active)Experimental Treatment1 Intervention
This is a single-arm, non-randomized study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PillSense
2021
N/A
~140
Find a Location
Who is running the clinical trial?
DatabeanIndustry Sponsor
4 Previous Clinical Trials
201 Total Patients Enrolled
EnteraSense LimitedLead Sponsor
2 Previous Clinical Trials
40 Total Patients Enrolled
David CollinsStudy DirectorTechnical Operations Director
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger